338 related articles for article (PubMed ID: 19372578)
1. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
McCord AM; Jamal M; Shankavaram UT; Lang FF; Camphausen K; Tofilon PJ
Mol Cancer Res; 2009 Apr; 7(4):489-97. PubMed ID: 19372578
[TBL] [Abstract][Full Text] [Related]
2. The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.
Jamal M; Rath BH; Tsang PS; Camphausen K; Tofilon PJ
Neoplasia; 2012 Feb; 14(2):150-8. PubMed ID: 22431923
[TBL] [Abstract][Full Text] [Related]
3. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
4. Girdin maintains the stemness of glioblastoma stem cells.
Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T
Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
6. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors.
Guichet PO; Bieche I; Teigell M; Serguera C; Rothhut B; Rigau V; Scamps F; Ripoll C; Vacher S; Taviaux S; Chevassus H; Duffau H; Mallet J; Susini A; Joubert D; Bauchet L; Hugnot JP
Glia; 2013 Feb; 61(2):225-39. PubMed ID: 23047160
[TBL] [Abstract][Full Text] [Related]
7. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
8. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
9. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
10. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines.
McCord AM; Jamal M; Williams ES; Camphausen K; Tofilon PJ
Clin Cancer Res; 2009 Aug; 15(16):5145-53. PubMed ID: 19671863
[TBL] [Abstract][Full Text] [Related]
11. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
12. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
Yan X; Ma L; Yi D; Yoon JG; Diercks A; Foltz G; Price ND; Hood LE; Tian Q
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1591-6. PubMed ID: 21220328
[TBL] [Abstract][Full Text] [Related]
13. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
14. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
15. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells.
Yao Y; Tao R; Wang X; Wang Y; Mao Y; Zhou LF
Neuro Oncol; 2009 Dec; 11(6):757-66. PubMed ID: 19264916
[TBL] [Abstract][Full Text] [Related]
16. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
17. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
[TBL] [Abstract][Full Text] [Related]
18. BMI1 sustains human glioblastoma multiforme stem cell renewal.
Abdouh M; Facchino S; Chatoo W; Balasingam V; Ferreira J; Bernier G
J Neurosci; 2009 Jul; 29(28):8884-96. PubMed ID: 19605626
[TBL] [Abstract][Full Text] [Related]
19. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.
Kahlert UD; Maciaczyk D; Dai F; Claus R; Firat E; Doostkam S; Bogiel T; Carro MS; Döbrössy M; Herold-Mende C; Niedermann G; Prinz M; Nikkhah G; Maciaczyk J
J Neuropathol Exp Neurol; 2012 Dec; 71(12):1086-99. PubMed ID: 23147506
[TBL] [Abstract][Full Text] [Related]
20. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
Shin JH; Lee YS; Hong YK; Kang CS
J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]